ClinicalTrials.gg
CompletedNCT02289768Updated Aug 5, 2016

Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses

A Phase 3 interventional study of 5-fluorouracil/salicylic acid and Vehicle in Actinic Keratosis, sponsored by Almirall, S.A.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-08-05.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fluorouracil in Keratosis, Actinic — 3 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Keratosis, Actinic.

Enrollment
7th of 19
166 · median 60
Started
2014
with 2 others
Phase 3
9 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
1 of 19
Almirall, S.A.

Among the 19 studies testing fluorouracil in Keratosis, Actinic, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 10th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

3 of the 19 studies testing fluorouracil in Keratosis, Actinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluorouracil in Keratosis, Actinic, or all of them as a file.
02

Study summary

The main purpose of this vehicle-controlled study is to determine the efficacy and safety of a solution of Actikerall® (containing 5-fluorouracil 0.5% and salicylic acid 10.0%) in the field-directed treatment of grade I-II actinic keratosis, when it is applied to the affected area once daily for 12 weeks.

A secondary objective of this study is to evaluate the efficacy of Actikerall® solution on subclinical actinic keratosis lesions in a subset of patients.

03

Conditions studied

  • Actinic Keratosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or non-pregnant, non-lactating (in the last 3 months) female aged between 18 and 85 years (both inclusive). Women of will follow specific study requirements.
  • Patients with at least 4 but not more than 10 clinically confirmed actinic keratoses lesions grade I or II (according to Olsen EA et al. 1991) within a field of cancerization of 25 cm² in the face/forehead or bald scalp.
  • Patients with skin type I to IV (according to Fitzpatrick Skin Types)
  • Patients free of any significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment area that may interfere with area examination or final evaluation.
  • Patients in good health condition or free of medical conditions that may interfere with the study results as confirmed by a physical examination, medical history and laboratory analysis.
  • Patients who accept to refrain from sunbathing, intense UV-light exposure and the solarium during the study duration.
  • Patients willing to stop using moisturizers and topical treatments with anti-aging products, vitamins A, C, and/or E containing ointments and gels and green tea preparations in the treatment area.
  • Patients able (physical ability or supportive person) to apply the study preparations correctly and to follow the study procedure and restrictions.
  • Patients with at least 3 subclinical lesions in the 25 cm² test area (field) clearly separated from each other and the actinic keratoses lesions (additional inclusion criteria for the patients participating on the sub-clinical lesions sub-study).

Exclusion criteria

Exclusion Criteria:

  • Subjects that have received treatment for actinic keratoses within the treatment area in the 3 months previous to Visit 1 (screening).
  • Subjects that have received prohibited pharmacological or non-pharmacological treatments for any indication other than actinic keratoses within the treatment area before randomization (Visit 2).
  • Subjects that have received prohibited systemic treatments for any indication before randomization (Visit 2).
  • Subjects taking phenytoin, methotrexate or sulfonylurea.
  • Subjects with dermatological diseases in the treatment area or surrounding area that may be exacerbated by the study treatment or may interfere the study assessments (e.g. psoriasis, eczema).
  • Subjects that have currently malignant or benign tumors of the skin within the treatment area (e.g., malignant melanoma, basal cell carcinoma, squamous cell carcinoma).
  • Subjects that suffer from any kind of photodermatoses.
  • Subjects that have evidence of unstable medical conditions.
  • Subjects with known to any of the trial drugs (5-fluorouracil, salicylic acid), to ingredients of the trial formulation, or to drugs of similar chemical classes
  • Subjects with allergy against dimethylsulfoxide, ethanol, ethyl acetate, pyroxyline, poly(butyl)methacrylate, and/or methylmethacrylate.
  • Subjects with dihydropyrimidine dehydrogenase deficiency (DPD deficiency).
  • Subjects that are currently participating or have participated within the 8 weeks prior to Visit 1 in another clinical trial.
  • Patients with known drug or alcohol abuse as assessed by the investigator within the 2 years prior to Visit 1.
  • Subject is institutionalized because of legal or regulatory order.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    5-fluorouracil/salicylic acid

    Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks

    Drug: 5-fluorouracil/salicylic acid

  • Placebo comparator
    Vehicle

    Vehicle solution applied to the affected area once-daily for 12 weeks

    Drug: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients with complete clinical clearance of actinic keratosis lesions in the treatment field

    Complete Clinical Clearance is defined as no clinically visible actinic keratosis lesions in the selected treatment area

    Time frame: Week 20

Secondary outcomes

  1. Percentage of patients with partial clinical clearance of actinic keratosis lesions in the treatment field

    Partial clearance is defined as a 75% or greater reduction in the number of clinically visible actinic keratosis lesions in the selected treatment area

    Time frame: Week 20

  2. Percentage change from baseline in the total number of actinic keratosis lesions

    Time frame: Week 20

  3. Global assessment of efficacy by the physician (Physician Global Assessment)

    Time frame: Week 20

  4. Change from baseline in total score of the Dermatology Life Quality Index (DLQI)

    Time frame: Week 20

  5. Total score of the patients´ treatment satisfaction questionnaire for medication (TSQM)

    Time frame: Week 20

  6. Percentage of patients with complete clearance of three pre-defined subclinical actinic keratosis lesions

    Sub-clinical lesions will be determined using reflectance confocal microscopy in a subset of 30 patients

    Time frame: Week 20

  7. Percentage change from baseline in the three selected actinic keratosis subclinical lesions

    Sub-clinical lesions will be determined using reflectance confocal microscopy in a subset of 30 patients

    Time frame: Week 20

  8. Percentage of patients for which the clearance of one pre-defined representative clinical actinic keratosis lesion is confirmed by reflectance confocal microscopy

    Determined using reflectance confocal microscopy in a subset of 30 patients

    Time frame: Week 20

  9. The number of patients with adverse events

    Time frame: Week 20

07

Study locations

14 sites
  • Almirall Investigational Site #3
    Berlin, 10117, Germany
  • Almirall Investigational Site #5
    Berlin, 13055, Germany
  • Almirall Investigational Site #4
    Berlin, 13507, Germany
  • Almirall Investigational Site #1
    Bochum, 44791, Germany
  • Almirall Investigational Site #8
    Bochum, 44803, Germany
  • Almirall Investigational Site #6
    Bonn, 53111, Germany
  • Almirall Investigational Site #9
    Dülmen, 48249, Germany
  • Almirall Investigational Site #10
    Friedrichshafen, 88045, Germany
  • Almirall Investigational Site #2
    Selters, 56242, Germany
  • Almirall Investigational Site #7
    Wuppertal, 42275, Germany
  • Almirall Investigational Site #11
    Leicester, LE10 2SE, United Kingdom
  • Almirall Investigational Site #12
    Nantwich, CW5 5NX, United Kingdom
  • Almirall Investigational Site #13
    Penzance, TR18 4JH, United Kingdom
  • Almirall Investigational Site #14
    Penzance, TR19 7HX, United Kingdom
08

References and documents

Publications

  • Stockfleth E, von Kiedrowski R, Dominicus R, Ryan J, Ellery A, Falques M, Ivanoff N, Azeredo RR. Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. Dermatol Ther (Heidelb). 2017 Mar;7(1):81-96. doi: 10.1007/s13555-016-0161-2. Epub 2016 Dec 19. Erratum In: Dermatol Ther (Heidelb). 2017 Jun;7(2):263. doi: 10.1007/s13555-017-0179-0. PubMed 27995485 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2014
First posted
Nov 13, 2014
Start
Oct 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Aug 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02289768
Lead sponsor
Almirall, S.A.
Collaborators
Almirall Hermal GmbH
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Oct 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Aug 5, 2016

Study contacts

Wolf-Godehard Ocker
study director · Almirall Hermal GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Salicylic Acid

Start the discussion